BioSpace News Archive

Immunome, Inc. announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price to the public of $20.00 per share.

Delcath Systems, Inc. announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January 2024.

YS Biopharma Co., Ltd., a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, announced the results of its extraordinary general meeting held on February 16, 2024 in Seattle, United States.

AstraZeneca’s TAGRISSO® with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

IGC Pharma, Inc. announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023.